These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9625452)

  • 1. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
    Akimoto S; Furuya Y; Akakura K; Ito H
    Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
    Akimoto S; Akakura K; Shimazaki J
    Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
    Akimoto S; Inomiya H; Furuya Y; Akakura K; Ito H
    Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Prostate; 1999 Jan; 38(1):28-34. PubMed ID: 9973106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
    Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
    Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen.
    Kataoka A; Yuasa T; Kageyama S; Tsuchiya N; Habuchi T; Iwaki H; Narita M; Okada Y; Yoshiki T
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):480-4. PubMed ID: 16909972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
    Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
    Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collagen derived serum markers in carcinoma of the prostate.
    Rudnicki M; Jensen LT; Iversen P
    Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M; Fukunaga M; Ohtawa T; Harada T
    World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients.
    Akimoto S; Okumura A; Fuse H
    Endocr J; 1998 Apr; 45(2):183-9. PubMed ID: 9700471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer.
    Westerhuis LW; Delaere KP
    Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):89-94. PubMed ID: 9056749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
    Kylmälä T; Tammela TL; Risteli L; Risteli J; Kontturi M; Elomaa I
    Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer.
    Noguchi M; Yahara J; Noda S
    Urology; 2003 May; 61(5):993-8. PubMed ID: 12736022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of osteoarthritis on serum marker levels of bone formation and resorption in patients with benign prostatic hypertrophy.
    Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
    Int J Urol; 1997 Nov; 4(6):580-2. PubMed ID: 9477188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer.
    Koga H; Naito S; Koto S; Sakamoto N; Nakashima M; Yamasaki T; Noma H; Kumazawa J
    Prostate; 1999 Apr; 39(1):1-7. PubMed ID: 10221259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.